Trials
4 active
4 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule”In the company’s words, NCT06194799 on ClinicalTrials.gov
- Tested for
- Lewy Body Dementia Psychosis (2 trials), Alzheimer's Disease Psychosis (2 trials)
- Main trialPhase 3
- “A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)”In the company’s words, NCT07095465 on ClinicalTrials.gov
Other drugs for Alzheimer's Disease Psychosis
- ML-007C-MAMapLight Therapeutics · Phase 2
- LY03017Luye Pharma Group Ltd. · Phase 1
Coming up4
- Jan 2028Phase 2/3 trial completes · ClinicalTrials.gov
- Feb 2028Phase 2 trial completes · ClinicalTrials.gov
- Feb 2029Phase 3 trial completes · ClinicalTrials.gov
- Apr 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2029 | Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | |
| Phase 3Enrolling by invitation | Apr 2029 | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | |
| Phase 2/3Recruiting | Jan 2028 | ACP-204 in Adults With Alzheimer's Disease Psychosis | |
| Phase 2Recruiting | Feb 2028 | Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026